Social media and COVID-19-perceptions and public deceptions of ivermectin, colchicine and hydroxychloroquine : lessons for future pandemics

dc.contributor.authorSchellack, Natalie
dc.contributor.authorStrydom, Morne A.
dc.contributor.authorPepper, Michael Sean
dc.contributor.authorHerd, Candice Lee
dc.contributor.authorHendricks, Candice Laverne
dc.contributor.authorBronkhorst, Elmien
dc.contributor.authorMeyer, Johanna C.
dc.contributor.authorPadayachee, Neelaveni
dc.contributor.authorBangalee, Varsha
dc.contributor.authorTruter, Ilse
dc.contributor.authorEllero, Andrea Antonio
dc.contributor.authorMyaka, Thulisa
dc.contributor.authorNaidoo, Elysha
dc.contributor.authorGodman, Brian
dc.contributor.emailnatalie.schellack@up.ac.zaen_US
dc.date.accessioned2023-04-24T09:33:00Z
dc.date.available2023-04-24T09:33:00Z
dc.date.issued2022-04
dc.descriptionSUPPLEMENTARY MATERIAL : TABLE S1: Ivermectin Raw Utilisation Data; TABLE S2: Chloroquine Raw Utilisation Data; TABLE S3: Chloroquine Utilisation Data; TABLE S4: Colchicine Raw Utilisation Data; TABLE S5: Colchicine Time Series Utilisation Data; TABLE S6: Clinical trials within South Africa; TABLE S7: Global Chloroqine Clinical Trials; TABLE S8: Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19); TABLE S9: Global Ivermectin Clinical Trials; TABLE S10: Global Multi-drug Clinical Trials; TABLE S11: Clinical Trial Registration Dates; Table S12: Number of trials by status.en_US
dc.description.abstractThe capacity for social media to influence the utilization of re-purposed medicines to manage COVID-19, despite limited availability of safety and efficacy data, is a cause for concern within health care systems. This study sought to ascertain links between social media reports and utilization for three re-purposed medicines: hydroxychloroquine (HCQ), ivermectin and colchicine. A combined retrospective analysis of social media posts for these three re-purposed medicines was undertaken, along with utilization and clinical trials data, in South Africa, between January 2020 and June 2021. In total, 77,257 posts were collected across key social media platforms, of which 6884 were relevant. Ivermectin had the highest number of posts (55%) followed by HCQ (44%). The spike in ivermectin use was closely correlated to social media posts. Similarly, regarding chloroquine (as HCQ is not available in South Africa), social media interest was enhanced by local politicians. Sentiment analysis revealed that posts regarding the effectiveness of these repurposed medicines were positive. This was different for colchicine, which contributed only a small number of mentions (1%). Of concern is that the majority of reporters in social media (85%) were unidentifiable. This study provides evidence of social media as a driver of re-purposed medicines. Healthcare professionals have a key role in providing evidence-based advice especially with unidentifiable posts.en_US
dc.description.departmentImmunologyen_US
dc.description.departmentPharmacologyen_US
dc.description.librarianam2023en_US
dc.description.sponsorshipPartly funded by the South African Medical Council (Extramural Unit, Stem Cell Research and Therapy) and the University of Pretoria (through the Institute for Cellular and Molecular Medicine), The Professor Bongani Mayosi Netcare Clinical Scholarship, The National Research Foundation and the University of Pretoria through the Institute for Cellular and Molecular Medicine. Other funding was provided by the different authors academic research funds.en_US
dc.description.urihttps://www.mdpi.com/journal/antibioticsen_US
dc.identifier.citationSchellack, N.; Strydom, M.; Pepper, M.S.; Herd, C.L.; Hendricks, C.L.; Bronkhorst, E.; Meyer, J.C.; Padayachee, N.; Bangalee, V.; Truter, I.; et al. Social Media and COVID-19—Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics. Antibiotics 2022, 11, 445. https://DOI.org/10.3390/antibiotics11040445.en_US
dc.identifier.issn2079-6382
dc.identifier.other10.3390/antibiotics11040445
dc.identifier.urihttp://hdl.handle.net/2263/90438
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en_US
dc.subjectSocial mediaen_US
dc.subjectRe-purposeden_US
dc.subjectMedicinesen_US
dc.subjectHydroxychloroquineen_US
dc.subjectIvermectinen_US
dc.subjectColchicineen_US
dc.subjectSentiment analysisen_US
dc.subjectUtilizationen_US
dc.subjectClinical trialsen_US
dc.subjectSouth Africa (SA)en_US
dc.subjectCOVID-19 pandemicen_US
dc.subjectCoronavirus disease 2019 (COVID-19)en_US
dc.titleSocial media and COVID-19-perceptions and public deceptions of ivermectin, colchicine and hydroxychloroquine : lessons for future pandemicsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Schellack_Social_2022.pdf
Size:
16.56 MB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Schellack_SocialSuppl_2022.xlsx
Size:
347.98 KB
Format:
Microsoft Excel XML
Description:
Supplementary Material

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: